Tumor-associated peptide antigen presented on major histocompatibility complex molecule (None established)

Tumor-associated peptide antigens presented on MHC molecules are peptides, frequently derived from mutated, overexpressed, or aberrantly modified tumor proteins, that are processed within the tumor cell and bound to MHC class I or II molecules for display on the cell surface[1][2][5]. These complexes are recognized by T cell receptors, triggering immune responses against tumor cells; the display of these peptides is essential for both natural immunosurveillance and the efficacy of immunotherapies, including peptide vaccines, checkpoint inhibitors, and adoptive T cell therapies[2][6][7]. Downregulation or loss of MHC presentation components allows many cancers to evade immune detection, representing a major therapeutic challenge[6][7]. The identification and characterization of specific tumor-peptide–MHC complexes underpins patient selection, efficacy monitoring, and the development of new targeted immunotherapies[2][6]. If you require a more granular listing (e.g., specifying MART-1 antigen or individual MHC allele), this class can be subdivided, but the principles remain as described above.

Other names

Tumor-associated antigens (TAAs) presented by MHCMHC-restricted tumor peptidesMHC-presented tumor epitopes

Drugs may enhance recognition or immune response to tumor-peptide–MHC complexes by T cells[2][7]. Inhibit immune checkpoints preventing T cell activation[6][7]. Provide exogenous tumor peptides for immune priming (vaccines)[2]. Restore or upregulate antigen presentation machinery lost in tumors (e.g., via drugs overcoming immune evasion)[6].